Calidi Biotherapeutics Approves Key Proposals at Annual Meeting

Calidi Biotherapeutics ( (CLDI) ) has provided an announcement.

On July 9, 2025, Calidi Biotherapeutics, Inc. held its Annual Meeting of Stockholders, where several key proposals were approved. The stockholders elected James Schoeneck and George Peoples as Class II Directors, ratified the appointment of CBIZ CPAs P.C. as the independent auditor for the fiscal year ending December 31, 2025, approved a reverse stock split at a ratio between 1-for-2 and 1-for-19, and amended the 2023 Equity Incentive Plan to increase the number of shares authorized for grant.

The most recent analyst rating on (CLDI) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.

Spark’s Take on CLDI Stock

According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.

Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.

To see Spark’s full report on CLDI stock, click here.

More about Calidi Biotherapeutics

Average Trading Volume: 13,847,105

Technical Sentiment Signal: Hold

Current Market Cap: $24.16M

See more insights into CLDI stock on TipRanks’ Stock Analysis page.